- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gaithersburg Today
By the People, for the People
Novavax Upgraded to Hold Rating
Wall Street Zen raises shares of biotech firm from Sell to Hold
Published on Feb. 28, 2026
Got story updates? Submit your updates here. ›
Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biotechnology company focused on developing next-generation vaccines, has been upgraded from a "sell" rating to a "hold" rating by analysts at Wall Street Zen in a research report issued on Saturday.
Why it matters
This rating change reflects the ongoing volatility and uncertainty surrounding Novavax's stock performance and future prospects as the company continues to develop its pipeline of vaccine candidates, including its lead product NVX-CoV2373 for COVID-19.
The details
In the research note, Wall Street Zen cited Novavax's recent financial results and pipeline updates as factors in their decision to upgrade the stock. Other equity research analysts have also weighed in on Novavax, with B. Riley Financial, BTIG Research, Weiss Ratings, and JPMorgan Chase & Co. providing a range of ratings from "buy" to "sell" and price targets from $6 to $19.
- The rating upgrade was issued on Saturday, February 28, 2026.
The players
Novavax, Inc.
A clinical-stage biotechnology company headquartered in Gaithersburg, Maryland that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases.
Wall Street Zen
An equity research firm that covers Novavax and other biopharmaceutical companies.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The upgrade of Novavax's rating to Hold by Wall Street Zen reflects the ongoing challenges and uncertainties facing the company as it works to advance its vaccine pipeline, particularly its lead COVID-19 candidate NVX-CoV2373. Investors will be closely watching for further updates on Novavax's progress and any potential shifts in analyst sentiment.
